Biomedical & Pharmacology Journal, March 2022. Vol. 15(1), p. 249-254 Published by Oriental Scientific Publishing Company © 2022 This is an Open Access article licensed under a Creative Commons license: Attribution 4.0 International (CC-BY). Serodetection of Cytomegalovirus and Epstein - Barr virus Antibodies Among Hemodialysis Patients Mohamed N. Ibrahim 1 , Mohamed S. Alhadi 2,3 and Waleed Y. Elbadawy 3 1 Clinical Laboratories department, College of Applied Medical Sciences, Jouf University, Qurayat, Saudi Arabia. 2 Biochemistry department, Faculty of Science, Ain Shams University, Egypt. 3 Hematology department, Wadii El-Nile Hospital, Cairo, Egypt. *Corresponding Author E-mail: mnabil@ju.edu.sa https://dx.doi.org/10.13005/bpj/2360 (Received: 31 October 2021; accepted: 04 February 2022) The infection with herpesviruses as Human herpes virus-5 (cytomegalovirus-CMV) and Human herpes virus-4 (Epstein – Barr virus -EBV) is one of the main causes of morbidity and mortality in hemodialysis patients. This study aims to investigate the serostatus of CMV and EBV in patients with renal failure who underwent hemodialysis. The study included 134 cases (55 females and 79 males) with an age range of 35-68 years (mean age 37.43±13.42 years). HCMV-IgG, IgM and EBV-IgG, EBV-IgM were determined in subjects' sera. 87 of 134 (65%) were underwent hemodialysis, while 47 (35%) had normal kidney functions without HCV infection. 68 (78.2%) and 31 (35.6%) cases out 87 hemodialysis patients were positive for CMV-IgG and IgM antibodies, respectively. On the other hand, 56.3% and 20.7% of the 87 hemodialysis patients were positive for EBV-IgG and IgM antibodies, respectively. There is no significant differences were observed between females and males in terms of seroprevelance rates. The rate of positive CMV-IgG among 48-64 years hemodialysis patients was high, Whereas, EBV-IgG were detected among 39-67 years. Our data suggest that seroprevalence of CMV and EBV antibodies among hemodialysis cases is a high and cause complications for these patients. Keywords: CMV-IgG, CMV-IgM, EBV-IgG and IgM for Hemodialysis Patients. Cytomegalovirus (CMV) is a worldwide virus which can cause severe morbidity and mortality in immunocompromised patients, such as AIDS patients, allograft recipients and patients with renal failure 1 . HCMV (HHV-5) is the prototype of subfamily betaherpesvirinae, like all herpes viruses in latency and persistence for lifetime of the individuals 2, 5 . CMV infection is almost asymptomatic or is followed by mild symptoms 3 . Reactivation of the virus occurs in immunosuppressed patients such as HIV cases, elderly patients, hemodialysis patients and subjects subjected to chemotherapy and ionized radiation treatment, and pregnant women, due to suppression of the immune system 1, 4 . The most common human infection in immunosuppressed patients is Epstein–Barr virus (EBV) infection and can lead to life-threatening lymphoproliferative diseases. The Epstein – Barr Virus has been implicated in several diseases, including infectious mononucleosis, African Burkitt lymphomas (BL), Hodgkin lymphoma, B-cell lymphomas of immunosuppressed cases, nasopharyngeal carcinomas (NPC) 6, 8 .